WO1991000724A1 - Alkynyle amines de regulation de la neurotransmission cholinergique - Google Patents

Alkynyle amines de regulation de la neurotransmission cholinergique Download PDF

Info

Publication number
WO1991000724A1
WO1991000724A1 PCT/US1990/003616 US9003616W WO9100724A1 WO 1991000724 A1 WO1991000724 A1 WO 1991000724A1 US 9003616 W US9003616 W US 9003616W WO 9100724 A1 WO9100724 A1 WO 9100724A1
Authority
WO
WIPO (PCT)
Prior art keywords
mmol
hydrogen
loweralkyl
nmr
pyrrolidinyl
Prior art date
Application number
PCT/US1990/003616
Other languages
English (en)
Inventor
John Y.-L. Chung
David S. Garvey
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of WO1991000724A1 publication Critical patent/WO1991000724A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/46—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention relates to compounds that regulate (stimulate or antagonize) cortical cholinerginc neurotransmission, processes for making such compounds, synthetic intermediates employed in these processes and methods for treating cognitive disorders or neurological and mental illnesses due to dysfunction of acetylcholine systems.
  • AD Alzheimer's Disease
  • cholinergic neurons in the basal forebrain has been linked to cortical cholinergic deficit using presynaptic
  • cholinergic markers in neocortex and hippocampus such as choline acetyltransferase activity, acetylcholinesterase activity and acetylcholine synthesis (P. J. Whitehouse et. al., CRC Crit. Rev. Clin. Neurobiol., 1, 319-339, (1985).
  • Postsynaptic muscarinic acetylcholine receptors are generally preserved in AD patients.
  • muscarinic cholinergic agonists capable of stimulating such sites directly are useful in correcting the cholinergic deficiency in AD and provide treatment of the memory impairment symptom of cerebral insufficiency
  • RS-86 RS-86
  • CNS penetration e.g., carbachol
  • known agents have many unwanted central agonist actions, including hypothermia, hypolocomotion and tremor.
  • Peripheral side effects include miosis,
  • R 26 is hydrogen, loweralkyl, aryl, alkanoyl, alkoxycarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl or an N-protecting group;
  • R3 is absent or -(C(R 6 ) (R 7 )) s - wherein R 6 and R 7 are independently selected at each occurrence from
  • R 21 and R 22 are independently selected from hydrogen and loweralkyl
  • R 23 is one, two or three substituents independently selected from
  • R 2 is defined as above,
  • R 23 is defined as above;
  • t 1 to 3
  • u 1 to 3.
  • R 26 is defined as above and R 27 is hydrogen or loweralkyl
  • e 1 to 6;
  • R 21 and R 22 are defined as above;
  • n 0, 1 or 2;
  • R 12 is
  • R 13 is
  • R 15 is independently selected at each occurrence from
  • R 23 is independently defined as above;
  • the dashed bond represents a single bond or a double bond.
  • the term "functionalized aminomethyl group” as used herein includes
  • R 16 and R 17 are independently selected from
  • R 23 is independently defined as above;
  • v 1 to 3;
  • R 23 is independently defined as above; and the dashed bond represents a single bond or a double bond.
  • R 23 is independently defined as above;
  • the dashed bond represents a single bond or a double bond.
  • loweralkyl refers to straight or branched chain radicals having from 1 to 7 carbon atoms including, but not limited to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, pentyl, hexyl, heptyl and the like.
  • alkenyl refers to a C 2 to C 12 straight or branched chain of carbon atoms which contains a carbon-carbon double bond including, but not limited to, allyl, propenyl, butenyl, isoprenyl and the like.
  • alkynyl refers to a C 2 to C 12 straight or branched chain of carbon atoms which contains a carbon-carbon triple bond including, but not limited to, propargyl, butynyl and the like.
  • alkoxy and thioalkoxy refer to -OR 30 and -SR 30 , respectively, wherein R 30 is a loweralkyl group.
  • phenoxy refers to -OR 31 wherein R 31 is phenyl.
  • substituted phenoxy refers to -OR 32 wherein R 32 is substituted phenyl as defined herein.
  • benzyloxy refers to -OCH 2 R 33 wherein R 33 is phenyl.
  • substituted benzyloxy as used herein is -OCH 2 R 34 wherein R 34 is substituted phenyl as defined herein.
  • alkanoyl refers to -C(O)R 35 wherein R 35 is a loweralkyl group.
  • alkoxycarbonyl refers to -C(O)OR 36 wherein R 35 is a loweralkyl group.
  • alkyaminocarbonyl refers to -C(O)NHR 37 wherein R 37 is a loweralkyl group.
  • dialkylaminocarbonyl refers to -C(O)NR 38 R 39 wherein R 38 and R 39 are independently selected from loweralkyl.
  • halo or halogen as used herein refers to fluoro, chloro , bromo, or iodo.
  • haloalkyl refers to a loweralkyl group in which one or more hydrogen atoms are substituted by halogen including, but not limited to, chloromethyl, trifluoromethyl, difluoroethyl and the like.
  • substituted phenyl refers to a phenyl group substituted with one, two or three substituents independently selected from loweralkyl, alkoxy, thioalkoxy, carboxy, alkoxycarbonyl, nitro, haloalkyl, hydroxy, amino, alkylamino and dialkylamino.
  • aryl or “aryl group” as used herein refers to a mono- or polycyclic aromatic carbocyclic fused or nonfused aromatic ring systems including, but not limited to, phenyl, naphthyl, indanyl, fluorenyl,
  • Aryl. groups can be unsubstituted or substituted with one, two or three substituents independently selected from loweralkyl, alkoxy, thioalkoxy, carboxy, alkoxycarbonyl, nitro, haloalkyl, hydroxy, amino, alkylamino and
  • arylalkyl refers to a loweralkyl radical to which is appended an aryl group.
  • N-protected or "N-protecting group” as used herein refers to those groups intended to protect the N-terminus of an amino acid or peptide or to protect an amino group against undesirable reactions during a synthetic procedure or to prevent the attack of
  • solubility of the compounds includes, but is not limited to sulfonyl, acetyl, pivaloyl, t-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), benzoyl or an L- or D- aminoacyl residue, which may itself be N-protected
  • the compounds of this invention can be prepared by a general synthetic scheme as illustrated in Scheme I.
  • N-protected acyclic or cyclic alpha-aminoaldehydes 1 prepared from the corresponding alpha-amino acids by the known technologies in the literature, are treated with triphenyl phosphine and carbon tetrabromide under the
  • N-protecting group can be removed by treatment with trifluoroacetic acid (TFA).
  • TFA trifluoroacetic acid
  • hydroxyl group in compounds 8 can be further elaborated.
  • compounds 12 are prepared from propargyl alcohols 8 in three steps: a Mitsunobu coupling with cyclic-imides 9 to give the imides 10, which are then subjected to NaBH4/MeOH reduction to give the hydroxy lactams 11, and the subsquent treatment of 11 with
  • any sensitive groups in the compounds may be protected in conventional manner.
  • suitable protecting groups for hydroxy groups include silyl groups such as trimethylsilyl or dimethyl-t-butylsilyl, and etherifying groups such as
  • Carboxy groups are preferably protected in a reduced form such as in the form of their corresponding protected alcohols, which may be subsequently oxidized to give the desired carboxy group.
  • Thio groups may be protected by disulfide
  • the protecting groups may be removed at any convenient stage in the synthesis of the desired compound according to conventional techniques.
  • N-tert-Butoxycarbonyl-(R)-prolinal The title compound was prepared from N-tert-butoxycarbonyl-(R)-proline via a diborane reduction as described by K. E. Rittle, C. F. Homnick, G. S.
  • reaction mixture was diluted with a mixture of EtOAc/hexane (1/1) and filtered through basic alumina (0.25 inch thick)/silica gel (0.5 inch thick, 40-60 micron). The filter cake was washed with a mixture of dicholoromethane/EtOAc/hexane (1/1/1). The filtrate was concentrated and the residue was taken up in ethyl
  • the compound was prepared from the product of EXAMPLE 5 using the conditions described in EXAMPLE 2.
  • Triphenylphosphine (16.8 g, 64 mmols) and carbon tetrabromide (8.5 g, 25.6 mmols) were combined in 21 mis of anhydrous methylene chloride and stirred at room temperature for 20 minutes.
  • the product from EXAMPLE 11c (2.7 g, 12.8 mmols) was then added under N 2 via cannula at a steady rate. After complete addition the reaction was allowed to stir for five minutes and then the entire reaction was poured over ethyl acetate/hexane (1:1). The slurry that resulted was filtered thru 1/4 inch basic aluminum oxide / 1/4 silica gel (40-63 m) via vacuum filtration.
  • the product was prepared from the product of EXAMPLE 11g using the same procedure as that described under EXAMPLE 1f. The crude was subjected to flash
  • the salt was prepared according to a similiar
  • the mixture could also be separated by HPLC with about 80% recovery.
  • S-isomer mp 112-114 °C
  • EXAMPLE 171 in the same manner as that in EXAMPLE 1e.
  • the crude was flash chromatographed using EtOAc/hexane (2:33:21:0) as the elutant.
  • a light yellow oil was
  • the oxalate salt of EXAMPLE 17n was made in 94% yield from a similiar procedure outlined under EXAMPLE 11i.
  • the title compound was prepared from the product of EXAMPLE 23a by the same procedure as that described under EXAMPLE 1b. The crude was flash columned using
  • the title compound was prepared from 1-tert-butoxycarbonyl-4(R)-(tert-butyldimethylsilyl)oxy-2(R)-(hyd roxymethyl)pyrrolidine (11.86 g, 35.77 mmol; prepared as described by Rosen et al in J . Med . Chem., 31 , 1598-1611 ,
  • the solution was saturated by the addition of solid NaCl and then it was extracted with ethyl acetate (3x) followed by CH 2 CI 2 (x1).
  • the combined organic phases were dried (Na 2 SO 4 ) and concentrated in vacuo.
  • the residue was dissolved in acetyl chloride (20 ml) and the stirred at reflux for 2 h. After concentration in vacuo, the residue was
  • EXAMPLE 32b (117.2 mg, 0.58 mmol) was reacted in a similar fashion to that described in EXAMPLE 30c.
  • EXAMPLE 47a (315 mg, 1.14 mmol), methanol ( ⁇ 100 ml), and 20% Pd/C was placed under 4 atm of hydrogen overnight. The catalyst was removed by filtration through paper and the filtrate was concentrated in vacuo to afford 220 mg ( ⁇ 100%) of a greenish brown solid;
  • the compounds of formula I regulate (stimulate or antagonize) cortical cholinergic neurotransmission and, therefore, are useful in treatment of cognitive disorders or neurological and mental
  • Such diseases due to dysfunction of acetylcholine systems. Such diseases include presenile and senile dementia, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania and Tourette Syndrome.
  • the compounds of this invention are also useful analgesic agents and are therefore useful in the treatment of severe painful conditions such as rheumatism, arthritis, and terminal illness.
  • muscarinic agonists and/or antagonists can be demonstrated in vitro using the following protocols.
  • the potencies of agonist binding at central M1 and M2 muscarinic binding sites were determined by analysis of competition with specific muscarinic receptor
  • the cerebral cortical M1 receptor was identified with [ 3 H]pirenzepine.
  • the muscarinic receptors of the pons-medulla are M2 in nature and were identified with [ 3 H]quinuclidinyl benzilate (QNB).
  • QNB [ 3 H]quinuclidinyl benzilate
  • Adult rat fronto-parietal cortex and pons-medulla were dissected free on an ice-block and homogenized (1:200 w/v) in 50 mM sodium-potassium phosphate buffer (pH 7.4) with a polytron.
  • radioligand was separated by vacuum filtration on Whatman GF/B glass fiber filters. Non-specific binding was defined as radioactivity remaining in the presence of 10 um atropine. Competition curves were analyzed with a four-parameter logistic program on a computer. The Ki value for the agonist was determined after correction of the IC 50 value for the presence of the radioligand.
  • Example 30 97 36
  • muscarinic agonists in brain tissue a pharmacological response assay employing rat striatum was employed.
  • Rat striatal muscarinic receptors are couple to the inhibition of cyclic AMP levels. This method is described in detail in D. J. Anderson and M. McKinney, Brain Res. 475:28-34, 1988.
  • the ATP stores in dissociated rat striatum was labeled with [ 3 H]adenine and [ 3 H]cyclic AMP levels were elevated with 10 um forskolin.
  • Muscarinic receptor activation with the agonist carbachol inhibits forskolin-activated levels of [ 3 H] cyclic AMP by about 40%.
  • inventions are central muscarinic receptor agonists.
  • the compounds of the present invention can be used in the form of salts derived from inorganic or organic acids.
  • These salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate,
  • camphorsulfonate digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptonate,
  • glycerophosphate hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate,
  • methanesulfonate nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate,
  • succinate tartrate, thiocyanate, tosylate, and
  • the basic nitrogen-containing groups can be quaternized with such agents as loweralkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.
  • loweralkyl halides such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides
  • dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates
  • long chain halides such
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the compounds of formula I which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base or acid with stoichiometric amounts or with an excess of the desired salt forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.
  • Example of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid.
  • Other salts include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.
  • the pharmaceutically acceptable salts of the acids of formula I are also readily prepared by conventional procedures such as treating an acid of formula I with an appropriate amount of a base, such as an alkali or
  • alkaline earth metal hydroxide e.g. sodium, potassium lithium, calcium, or magnesium
  • an organic base such as an amine, e.g., dibenzylethylenediamine, cyclohexylamine, dicyclohexylamine, trimethylamine, piperidine,
  • pyrrolidine benzylamine and the like, or a quaternary ammonium hydroxide such as tetramethylammonium hydroxide and the like.
  • the present invention includes one or more of the compounds of Formula (I) formulated into compositions together with one or more non-toxic pharmaceutically acceptable carriers, adjuvants or vehicles which are collectively referred to herein as carriers, for
  • a peripherally acting anti-cholinergic or anti-muscarinic agent such as N-methylscopolamine, N-methylatropine, propantheline, methantheline, or
  • compositions can be administered to humans and animals either orally, rectally, parenterally
  • compositions suitable for parenteral injection may comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or
  • aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols
  • compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents.
  • adjuvants such as preserving, wetting, emulsifying, and dispensing agents.
  • Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like.
  • isotonic agents for example sugars, sodium chloride and the like.
  • Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • the compounds can be incorporated into slow release or targeted delivery systems such as polymer matrices, liposomes, and microspheres. They may be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
  • Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules.
  • the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or
  • fillers or extenders as for example, starches, lactose, sucrose, glucose, mannitol and silicic acid
  • binders as for example, carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose and acacia
  • humectants as for example, glycerol
  • disintegrating agents as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates and sodium carbonate
  • solution retarders as for example paraffin
  • absorption accelerators as for example, quaternary ammonium compounds
  • wetting agents as
  • compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycos, and the like.
  • Solid dosage forms such as tablets, dragees, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings and others well known in this art. They may contain opacifying agents, and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedding
  • compositions which can be used are polymeric substances and waxes.
  • the active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the
  • Liquid dosage forms for oral administratin include pharmaceutically acceptable emulsions, solutions,
  • the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oili, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan or mixtures of these substances, and the like.
  • inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, eth
  • composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.
  • Suspensions in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum
  • metahydroxide bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
  • compositions for rectal administrations are preferably suppositories which can be prepared by mixing the
  • non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt in the rectum or vaginal cavity and release the active component.
  • Dosage forms for topical administration of a compound of this invention include powders, sprays and inhalants.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservative, buffers or propellants as may be required.
  • Ophthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
  • the present compounds can also be administered in the form of liposomes.
  • liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposones can be used.
  • the present compositions in liposome form can contain, in addition to the compounds of the present invention, stabilizers, preservatives, excipients, and the lik.
  • the preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic.
  • compositions of the invention may be varied so as to obtain an amount of active ingredient that is effective to obtain a desired therapeutic response for a particular compostion and method of administration.
  • the selected dosage level therefore depends upon the desired
  • Total daily dose of the compounds of this invention administered to a host in single or divided doses may be in amounts, for example, of from about 0.001 to 100 mg/kg body weight daily and preferably 0.01 to 10 mg/kg/day. Dosage unit compositions may contain such amounts of submultiples thereof to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the body weight, general health, sex, diet, time and route of administration, rates of

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un composé de régulation de la neurotransmission cholinergique corticale ayant la formule (I), dans laquelle A représente (1) une lactame fonctionnalisée; (2) un groupe azacycloalkyle fonctionnalisé; (3) un groupe carbonylaminométhyle fonctionnalisé; ou (4) un groupe oxyalkyle fonctionnalisé; et B représente (1) un groupe pyrrolidine-2-yl fonctionnalisé; (2) un groupe aminométhyle fonctionnalisé; (3) un hétérocycle à 5 membres contenant deux hétéro-atomes; ou (4) un dérivé de pipéridine, ou son sel pharmaceutiquement acceptable.
PCT/US1990/003616 1989-07-06 1990-06-26 Alkynyle amines de regulation de la neurotransmission cholinergique WO1991000724A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37632689A 1989-07-06 1989-07-06
US376,326 1989-07-06

Publications (1)

Publication Number Publication Date
WO1991000724A1 true WO1991000724A1 (fr) 1991-01-24

Family

ID=23484560

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/003616 WO1991000724A1 (fr) 1989-07-06 1990-06-26 Alkynyle amines de regulation de la neurotransmission cholinergique

Country Status (4)

Country Link
GR (1) GR900100519A (fr)
IE (1) IE902294A1 (fr)
PT (1) PT94622A (fr)
WO (1) WO1991000724A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
WO2002039997A2 (fr) * 2000-11-01 2002-05-23 Millennium Pharmaceuticals, Inc. Composes modulant ace-2 et procedes d'utilisation associes
US6462222B1 (en) 1996-12-18 2002-10-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Aminoindan derivatives
US7045532B2 (en) 1999-04-30 2006-05-16 Millennium Pharmaceuticals, Inc. ACE-2 modulating compounds and methods of use thereof
US7625946B2 (en) 2006-02-24 2009-12-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Propargylated aminoindans, processes for preparation, and uses thereof
US8420696B2 (en) 2005-12-09 2013-04-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of low-dose ladostigil for neuroprotection
WO2014202994A1 (fr) * 2013-06-21 2014-12-24 The University Court Of The University Of Edinburgh Composés et procédés bio-orthogonaux

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856790A (en) * 1970-01-06 1974-12-24 American Home Prod Cyclic amides of 1,4-diaminobut-2-yne
US3959311A (en) * 1967-11-09 1976-05-25 Aktiebolaget Astra Oxotremorine antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959311A (en) * 1967-11-09 1976-05-25 Aktiebolaget Astra Oxotremorine antagonists
US3856790A (en) * 1970-01-06 1974-12-24 American Home Prod Cyclic amides of 1,4-diaminobut-2-yne

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
(AMSTUTZ et al.), HELVETICA CHIMICA ACTA, Volume 70, 1987, pages 2232-224. *
(KARLEN et al.), JOURNAL OF MEDICINAL CHEMISTRY, Volume 13, pages 651-657, 1970. *
(LEVY et al.), THERAPIC, 1967, Volume XXII, pages 671-688. *
(LINDEKE et al.), ACTA PHARM. SUEC., Volume 24, pages 161-168, 1987. *
(LUNDKVIST et al.), JOURNAL OF MEDICINAL CHEMISTRY, Volume 32, pages 863-869, 1989. *
(MOSES et al.), ACTA PHARM. SUEC., 1978, Volume 15, pages 175-180. *
(NEUMEYER et al.), JOURNAL OF MEDICINAL CHEMISTRY, Volume 10, pages 615-620, 1967. *
(RINGDAHL et al.), JOURNAL OF MEDICINAL CHEMISTRY, Volume 32, pages 659-663, 1989. *
(RINGDAHL et al.), JOURNAL OF PHARMACOLOGY & EXPERIMENTAL THERAPEUTICS, Volume 249, pages 210-215, 1989. *
(RINGDAHL.), EUROPEAN JOURNAL OF PHARMACOLOGY, Volume 99, pages 177-184, 1984. *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
US6462222B1 (en) 1996-12-18 2002-10-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Aminoindan derivatives
US6538025B2 (en) 1996-12-18 2003-03-25 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
USRE39616E1 (en) 1996-12-18 2007-05-08 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
US7045532B2 (en) 1999-04-30 2006-05-16 Millennium Pharmaceuticals, Inc. ACE-2 modulating compounds and methods of use thereof
WO2002039997A2 (fr) * 2000-11-01 2002-05-23 Millennium Pharmaceuticals, Inc. Composes modulant ace-2 et procedes d'utilisation associes
WO2002039997A3 (fr) * 2000-11-01 2002-11-28 Millennium Pharm Inc Composes modulant ace-2 et procedes d'utilisation associes
US8420696B2 (en) 2005-12-09 2013-04-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of low-dose ladostigil for neuroprotection
US7625946B2 (en) 2006-02-24 2009-12-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Propargylated aminoindans, processes for preparation, and uses thereof
US8609719B2 (en) 2006-02-24 2013-12-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Propargylated aminoindans, processes for preparation, and uses thereof
WO2014202994A1 (fr) * 2013-06-21 2014-12-24 The University Court Of The University Of Edinburgh Composés et procédés bio-orthogonaux

Also Published As

Publication number Publication date
PT94622A (pt) 1991-03-20
GR900100519A (el) 1991-12-10
IE902294A1 (en) 1991-01-16

Similar Documents

Publication Publication Date Title
EP0123444B1 (fr) Dérivés 4-substitués de 2-azétidinone, procédé pour la fabrication de dérivés et médicament contenant les dérivés
RU2083574C1 (ru) Полициклические аминосодержащие соединения или их соли, их оптически чистые изомеры, способ получения полициклических аминосодержащих соединений, циклические аминосодержащие соединения или их соли, их оптически чистые изомеры и фармацевтическая композиция, обладающая антагонистической активностью к рецепторам нейрокинина
US6436928B1 (en) Selective neurokinin antagonists
RU2478094C2 (ru) Замещенные n-фенил-бипирролидинмочевины и их терапевтическое применение
MXPA06012831A (es) Nuevos compuestos de derivados de morfolina y prolina.
US5344940A (en) Intermediates for individual stereoisomers of 7-[3-(aminoalkyl)-1-pyrrolidinyl]-quinolones and naphthyridones
MXPA06001559A (es) Inhibidores de amina ciclica bace-1 que poseen una benzamida como sustituyente.
HRP970426A2 (en) Fluorine containing 1,4-disubstituted piperidine derivatives
JPH10506900A (ja) ファルネシル−タンパク質トランスフェラーゼ阻害剤
WO2004076434A1 (fr) Inhibiteurs de dipeptidyl peptidases
US20090062251A1 (en) Novel Compounds 002
RU2156763C2 (ru) Азотсодержащие гетероциклические производные, фармацевтическая композиция на их основе и способ лечения или профилактики тромботических заболеваний
RU2158264C2 (ru) 3-азетидинилалкилпиперидины или пирролидины в качестве антагонистов тахикинина, способы их получения, промежуточные соединения, фармацевтическая композиция на их основе и способ лечения
CA2256438C (fr) Derives d'amidine aromatique utiles en tant qu'inhibiteurs selectifs de la thrombine
JP2009167215A (ja) 新規ジアリールアルケン誘導体及び新規ジアリールアルカン誘導体
AU2010234610B2 (en) Serotonin and norepinephrine reuptake inhibitor
US20080262075A1 (en) Pyrrolidine Derivatives as Muscarinic Receptor Antagonists
WO1991000724A1 (fr) Alkynyle amines de regulation de la neurotransmission cholinergique
WO1999012914A1 (fr) Derives de thiouree
EP0559774B1 (fr) Stereoisomeres individuels de 7- 3-(aminoalkyl)-1-pyrrolidinyl]-quinolones et de naphtyridones utilises comme agents antibacteriens
KR20160101194A (ko) 정신 장애의 치료를 위한 (r)-3-((3s,4s)-3-플루오로-4-(4-히드록시페닐)피페리딘-1-일)-1-(4-메틸벤질)피롤리딘-2-온 및 그의 전구약물
JP3916093B2 (ja) 光学活性イミダゾリジノン誘導体とその製造方法
EP0690850A1 (fr) Derives de la morpholine et de la thiomorpholine substitues en position 2 utilises comme antgonistes du gaba b
US5624939A (en) N-acyl pyrrolidines and drugs for the treatment or prevention of cholecystokinin and gastrin-related disorders
US5625060A (en) Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions on which they are present

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

NENP Non-entry into the national phase

Ref country code: CA